QTVascular

MEDIA RELEASE

FINAL RESULTS FROM BELOW-THE-KNEE COHORT IN CHOCOLATE REGISTRY PRESENTED AT THE 5TH ANNUAL AMPUTATION PREVENTION CONFERENCE

Highlights:

- **Chocolate® Balloon Angioplasty Registry represents one of the largest single studies ever conducted of interventions in patients with below-the-knee arterial disease**
- **Dr. Jihad Mustapha, Principal Investigator, concluded that treatment with Chocolate® PTA shows improved outcomes when compared to use of traditional PTA balloons in similar populations**

SINGAPORE, 24 August 2015 – QT Vascular Ltd., together with its subsidiaries (the "**Company**" or "**QT Vascular**", and together with its subsidiaries, the "**Group**"), a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announced today the final results of the below-the-knee ("BTK") cohort of patients in the Chocolate® Balloon Angioplasty Registry ("BAR") which were presented on August 15 2015 at the 5th Annual Amputation Prevention Symposium in Chicago, Illinois by the Principal Investigator, Dr. Jihad Mustapha, of Metro Health Hospital, Wyoming, Michigan.

Based on historical outcomes with conventional balloon angioplasty reported in the literature [1-3], BTK patients treated with Chocolate® percutaneous transluminal angioplasty ("PTA") Balloon Catheter ("Chocolate® PTA") in this study showed a lower rate of unplanned stenting, a lower rate of repeat interventions, a lower incidence of amputation and lower overall mortality. A randomized controlled study would further define the potential treatment benefit of the Chocolate® PTA for BTK lesions.'

Outcomes	Chocolate® PTA	Conventional PTA [1-3]
Procedural		
Bail-out stent placement	4.9%	9.9%
30 days		
Target lesion revascularization	2.2%	8.1%
Major amputation	1.3%	4.4-6.6%
Mortality	0.9%	1.7-3.3%

Outcomes	Chocolate® PTA	Conventional PTA [1-3]
6 months		
Target lesion revascularization	9.0%	16.0%
Major amputation	3.2%	11.8%
Mortality	2.9%	7.7%

"A significant part of my practice is treating patients with BTK disease. These patients have more progressed disease and are often at risk for higher complication rate including amputation and even death," commented Dr. Mustapha. "The results from Chocolate® BAR are very positive. Drug coated balloons have not yet shown to be effective for interventions below the knee. With Chocolate® PTA, even without a drug, we now have the tool to improve outcomes in this very sick group of patients."

The Chocolate® BAR is an observational registry collecting data on real world use with the Chocolate® PTA to assess its effectiveness in achieving optimal PTA procedural outcomes and to assess potential longer-term clinical benefits. A total of 226 BTK patients were enrolled and agreed to undergo three months follow-up and a cohort of 123 patients was scheduled for six months follow-up. In addition, 264 above-the-knee ("ATK") patients were enrolled for a total of 490 patients treated at 33 US centers. The final results for the ATK patient cohort will be presented later in 2015.

"It is very gratifying to see patients treated with Chocolate® PTA to have low rates of bail-out stenting, repeat interventions, and amputations. The BTK patients are in a need for a solution and the results of the Chocolate® BAR are encouraging", stated Dr Eitan Konstantino, PhD, Chief Executive Officer of QT Vascular. "We are focused on continued innovation and believe that our pipeline of drug coated devices will add meaningful value to patients and healthcare providers."

~~ End ~~

1. Razavi MK, Mustapha JA, Miller LE. Contemporary systematic review and meta-analysis of early outcomes with percutaneous treatment for infrapopliteal atherosclerotic disease. *Jour of Vasc and Intervent Radiol : JVIR* 2014;25:1489-96, 96 e1-3.
2. Romiti M, Albers M, Brochado-Neto FC, Durazzo AE, Pereira CA, De Luccia N. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. *J Vasc Surg* 2008;47:975-81.
3. Boisers, Marc on behalf of AMS investigators. 6-Month Analysis AMS INSIGHT—Absorbable Metal Stent Implantation for Treatment of Below-the-Knee Critical Limb Ischemia: 6-Month Analysis. Cardiovasc Intervent Radiol (2009) 32:424–435 (PTA control group)

ABOUT QT VASCULAR LTD. (SGX Stock code: 5I0)

QT Vascular Ltd. together with its subsidiaries ("**QT Vascular**" or the "**Group**"), is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. QT Vascular works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes.

QT Vascular is based in Singapore with a US subsidiary, TriReme Medical LLC ("**TriReme Medical**"), based in Pleasanton, California. TriReme Medical's range of percutaneous transluminal angioplasty ("**PTA"**) and percutaneous transluminal coronary angioplasty ("**PTCA**") products include (i) Chocolate® PTA Balloon Catheter, (ii) Chocolate® PTCA Balloon Catheter, (iii) GliderXtreme™ PTA Balloon Catheter, (iv) GliderfleX® PTA Balloon Catheter; and (v) Glider™ PTCA Balloon Catheter, all of which have the CE Mark that allows them to be sold in Europe, and FDA clearance to be sold in the United States. Additionally, the GliderXtreme™ PTA Balloon Catheter has the regulatory clearance in China and Japan, while the Glider™ PTCA Balloon Catheter has the regulatory clearance in Japan. These products are mainly sold through its main distributors: (i) Cordis Corporation (a wholly-owned subsidiary of Johnson & Johnson), (ii) Shandong Weigao Group Medical Polymer Co Ltd and (iii) Century Medical, Inc.

The Group has also applied for CE marking approval with respect to the Chocolate® Touch, its advanced drug-coated peripheral balloon.

For more information, please visit the company website at www.qtvascular.com

---

Issued on behalf of **QT VASCULAR LTD.** by:

WATERBROOKS CONSULTANTS PTE LTD
Tel: +65 6100 2228

For media and analysts, please contact:

Mr Wayne Koo	(M): +65 9338 8166	wayne.koo@waterbrooks.com.sg
Ms Lynette Tan	(M): +65 9687 2023	lynette@waterbrooks.com.sg
Ms Angeline Cheong	(M): +65 9666 0977	angeline@waterbrooks.com.sg

---

Cautionary Note on Forward-Looking Statements

All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as "expect", "anticipate", "believe", "estimate", "intend", "project", "plan", "strategy", "forecast" and similar expressions or future or conditional verbs such as "if", "will", "would", "should", "could", "may" and "might". These statements reflect the Company's current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company undertakes any obligation to update publicly or revise any forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.

QT Vascular Ltd. (the "Company") was listed on Catalist board of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 29 April 2014. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income At Raffles, Singapore 049318, telephone +65 6229 8088.